INIZIA IL black FRIDAY 3 |15% su tutto con il coupon 15alcubo | SCOPRI di più

Customer care
  • Vicks Flu Action 200 + 30mg 12 Tablets -51%

Vicks Flu Action 200 + 30mg 12 Tablets

4.14€ 8.39€
  • Purchase 3 items for 4.06€ each
  • Purchase 4 items for 3.97€ each
  • Purchase 5 items for 3.89€ each

Vicks Flu Action 200 + 30mg Tablets


These tablets thanks to the active ingredients contained in it give symptomatic relief of nasal / sinus congestion with headache, fever and pain associated with colds and flu. Vicks Flu Action is indicated in adults and adolescents aged 15 years and older.


Dosage and method of taking vicks flu action tablets

Posology Adults and adolescents aged 15 years and over: 1 tablet (equivalent to 200 mg of ibuprofen and 30 mg of pseudoephedrine hydrochloride) every 4–6 hours as needed. For more severe symptoms, 2 tablets (equivalent to 400 mg of ibuprofen and 60 mg of pseudoephedrine hydrochloride) every 6–8 hours as needed, up to the maximum total daily dose. The maximum total daily dose of 6 tablets (equivalent to 1200 mg of ibuprofen and 180 mg of pseudoephedrine hydrochloride) should not be exceeded. Treatment should not exceed 5 days. This combination product should be used when both the decongestant action of pseudoephedrine hydrochloride and the analgesic and / or anti-inflammatory action of ibuprofen are required. If a symptom is predominant (nasal congestion or headache and / or fever), single active ingredient therapy is preferable. Consult your doctor if use of this medicine in adolescents is necessary for more than 3 days, or if symptoms worsen. In older patients and in patients with a history of ulcers, particularly if complicated with haemorrhage or perforation (see section 4.3), initiate therapy with the lowest possible dose because the risk of gastrointestinal bleeding, ulcer or perforation is greater as of the doses of NSAIDs. In these patients, or in patients taking other drugs that may increase the risk of gastrointestinal events (see below and section 4.5), concomitant use of protective agents (misoprostol or proton pump inhibitors) should be considered. In patients with renal or hepatic disorders it is necessary to adapt the dosage to the individual patient. The lowest effective dose should be used for the minimum duration necessary to relieve symptoms. Pediatric population Vicks Flu Action is contraindicated in children below 15 years of age (see section 4.3). Method of administration For oral use. The tablets should be swallowed with water, preferably on a full stomach. Do not break or crush the tablets.


What are the Active principles contained?

One tablet contains 200 mg of ibuprofen and 30 mg of pseudoephedrine hydrochloride (equivalent to 24.6 mg of pseudoephedrine) Excipients with known effect: Tartrazine dyes (E102, 0.47 mg / film-coated tablet). Sunset Yellow FCF (E110, 0.07 mg / film-coated tablet). Soy lecithin (E322, 0.37 mg / film-coated tablet). For the full list of excipients, see section 6.1.



Tablet core Microcrystalline cellulose Pregelatinised maize starch Povidone K-30 Silica, colloidal anhydrous Stearic acid 95 Croscarmellose sodium Sodium lauryl sulfate Film coating: Opadry II yellow Polyvinyl alcohol - Partially hydrolyzed Talc (E553b) Titanium dioxide (E 171) Tartrazol 3350 ) Soy Lecithin (E322) Sunset Yellow FCF (E110) Opadry fx Silver Polyvinyl Alcohol - Partially. hydrolyzed Talc (E553b) Titanium dioxide (E 171) Aluminum potassium silicate (E555) Titanium dioxide (E171) Polysorbate 80 (E433)



- Hypersensitivity to ibuprofen, pseudoephedrine or to any of the excipients listed in section 6.1. - Patients under the age of 15. - Pregnancy and lactation (see section 4.6). - A history of hypersensitivity reactions (e.g. bronchospasm, asthma, nasal polyposis, rhinitis or urticaria) associated with aspirin, other analgesics, antipyretics or other non-steroidal anti-inflammatory drugs (NSAIDs). - Active peptic ulcer or history of recurrent ulcer / haemorrhage (two or more distinct episodes of ulcer or bleeding with evidence). - History of gastrointestinal bleeding or perforation, including cases associated with NSAIDs. - Cerebrovascular haemorrhage or other type of haemorrhage. - Unexplained hematopoietic abnormalities. - Severe renal insufficiency. - Severe hepatic insufficiency. - Severe heart failure. - Severe cardiovascular disorder, coronary artery disease (heart disease, hypertension, angina pectoris), tachycardia, hyperthyroidism, diabetes, pheochromocytoma, - History of stroke or presence of risk factors for stroke (due to α – sympathomimetic activity of pseudoephedrine hydrochloride) . - Risk of closed-angle glaucoma. - Risk of water retention related to urethro-prostatic disorders. - History of myocardial infarction. - History of seizures. - Disseminated systemic lupus erythematosus. - Concomitant use of other vasoconstrictive drugs used as nasal decongestants, administered orally or nasally (e.g. phenylpropanolamine, phenylephrine and ephedrine), and methylphenidate (see section 4.5). - Concomitant use of NSAIDs or aspirin with a daily dose greater than 75 mg, analgesics and selective COX 2 inhibitors (see section 4.5). - Concomitant or previous use of monoamine oxidase inhibitors (MAOIs) within the previous 2 weeks (see section 4.5).



Concomitant use of Vicks Flu Action and other NSAIDs containing COX-2 inhibitors should be avoided. Undesirable effects can be reduced by using the lowest effective dose for the shortest time necessary to control symptoms (see "Gastrointestinal effects" and "Cardiovascular and cerebrovascular effects" below). Special warnings relating to pseudoephedrine hydrochloride • The dosage, the maximum recommended duration of treatment (5 days) and contraindications must be strictly observed (see section 4.8). • Patients should be advised that treatment should be discontinued if hypertension, tachycardia, palpitations, cardiac arrhythmias, nausea or any neurological signs appear as an onset or worsening of headache. Before using this product, patients should consult their physician in case of: • Hypertension, heart disease, hyperthyroidism, psychosis or diabetes. • Concomitant administration of anti-migraine drugs, in particular ergot alkaloid vasoconstrictors (due to the a – sympathomimetic activity of pseudoephedrine). • SLE and mixed connective tissue diseases: Systemic lupus erythematosus and mixed connective tissue diseases - increased risk of aseptic meningitis (see section 4.8). • Following the systemic administration of vasoconstrictors, particularly during febrile attacks or in case of overdose, cases of neurological symptoms such as convulsions, hallucinations, behavioral disturbances, agitation and insomnia have been described. Such symptoms were reported more commonly in the pediatric population. It is therefore advisable to: • avoid the administration of Vicks Flu Action both in combination with medicinal products capable of lowering the epileptogenic threshold, such as terpene derivatives, clobutinol, atropine-like substances and local anesthetics, and where there is a history of seizures ; • strictly adhere to the recommended dosage in all cases and inform patients of the risk of overdose if Vicks Flu Action is taken in combination with other vasoconstrictor-containing medicines. Patients with urethro-prostatic disorders are more prone to the development of symptoms such as dysuria and urinary retention. Elderly patients may be more sensitive to central nervous system (CNS) effects. Precautions for use related to pseudoephedrine hydrochloride : • In patients undergoing elective surgery during which volatile halogenated anesthetics will be used, it is preferable to discontinue Vicks Flu Action therapy several days before surgery due to the risk of acute hypertension (see section 4.5). • Athletes should be advised that pseudoephedrine hydrochloride treatment can cause positive doping test results. Interference with serological testing Pseudoephedrine has the potential to reduce iobenguane 131 I reuptake in neuroendocrine tumors, thus interfering with scintigraphy. Special warnings regarding ibuprofen In patients with, or with a history of bronchial asthma or allergies, ibuprofen can trigger bronchospasm. The product should not be administered in case of asthma without prior medical consultation (see section 4.3). Patients with asthma associated with chronic rhinitis, chronic sinusitis and / or nasal polyposis are at increased risk of allergic reactions with the intake of acetylsalicylic acid and / or NSAIDs. Administration of Vicks Flu Action may trigger an acute asthma attack, particularly in some patients allergic to acetylsalicylic acid or an NSAID (see section 4.3). There is a risk of kidney failure in dehydrated adolescents. Gastrointestinal Effects: Cases of gastrointestinal bleeding, ulceration or perforation, sometimes fatal, have been reported with all NSAIDs at any time during treatment, with or without warnings or a previous history of gastrointestinal events. The risk of gastrointestinal bleeding, ulcer or perforation, which can be fatal, is greater with increasing NSAID doses, in patients with a history of ulcer (particularly if complicated with haemorrhage or perforation - see section 4.3) and in patients of older age. over 60 years. These patients should start treatment at the lowest available dose. Combination therapy with gastroprotectors (e.g. misoprostol or proton pump inhibitors) should be considered for these patients and those taking concomitant treatment with low dose acetylsalicylic acid or other drugs that may increase gastrointestinal risk (see below). and paragraph 4.5). Patients with a history of gastrointestinal toxicity, particularly when elderly, may present with unusual abdominal symptoms (especially gastrointestinal bleeding) in the initial stages of treatment. Particular caution is advised in patients on concomitant therapy with drugs that can increase the risk of ulcer or bleeding such as oral corticosteroids, anticoagulants such as warfarin, SSRIs or antiplatelet agents such as acetylsalicylic acid (see section 4.5). Treatment with Vicks Flu Action should be discontinued immediately if gastrointestinal bleeding or ulcer occurs. NSAIDs should be administered with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions may worsen (see section 4.8) Concomitant use of alcohol and NSAIDs may increase drug related undesirable effects. active, especially those relating to the gastrointestinal tract or the central nervous system. Cardiovascular and cerebrovascular effects: Clinical trials and epidemiological data suggest that the use of ibuprofen, particularly at high doses (more than 2400 mg / day) and in long-term therapies, may be associated with a small increased risk of events. arterial thrombotics such as myocardial infarction or stroke. In general, epidemiological studies do not suggest that low-dose ibuprofen (less than 1200 mg / day) is associated with an increased risk of myocardial infarction. Caution is required in patients with a history of hypertension and / or heart failure because fluid retention, hypertension or edema have been reported in association with previous NSAID therapy; in such circumstances, you should contact your doctor and / or pharmacist before starting treatment. Skin reactions: Rare cases of serious and sometimes fatal skin reactions, including exfoliative dermatitis, Stevens – Johnson syndrome and toxic epidermal necrolysis, have been reported in association with the use of NSAIDs (see section 4.8). Patients are most at risk of these skin reactions in the early stages of treatment, as in most cases they occurred within the first month of treatment. Treatment with Vicks Flu Action should be discontinued when the first signs of a rash, mucosal lesions or any other signs of hypersensitivity appear. Precautions for use related to ibuprofen : • Elderly patients: The pharmacokinetics of ibuprofen are not changed with age, therefore dosage adjustments are not necessary in the elderly. However, elderly patients should be closely monitored as they are more sensitive to NSAID side effects, and in particular gastrointestinal bleeding and perforation, which can be fatal. • Special caution and medical supervision are required when administering ibuprofen to patients with a history of gastrointestinal disease (such as peptic ulcer, hiatus hernia or gastrointestinal bleeding). • During the initial stages of treatment, careful monitoring of urinary excretion and renal function is required in patients with heart failure, chronic impairment of renal or hepatic function, in patients on diuretic therapy, in those hypovolaemic due to major surgery and , in particular, in elderly patients. The renal function of these patients may be adversely affected by treatment with NSAIDs. • If visual disturbances occur during treatment, a complete ophthalmological examination will be required. If symptoms persist or worsen, the patient should see their doctor. Vicks Flu Action contains 0.28 mg of sodium per tablet. Vicks Flu Action contains soy lecithin. If you are allergic to soy or peanut oil, do not use this medicine. Vicks Flu Action contains the azo dyes tartrazine (E102) and Sunset Yellow (E110), which can cause allergic reactions.



Pregnancy: Vicks Flu Action is contraindicated in pregnancy (see section 4.3). Inhibition of prostaglandin synthesis can adversely affect pregnancy and / or embryonic / fetal development. Data from epidemiological studies suggest an increased risk of spontaneous abortion, cardiac malformation and gastroschisis following the use of a prostaglandin synthesis inhibitor during the first months of pregnancy. The absolute risk of cardiovascular malformation increased from less than 1% to approximately 1.5%. The risk is believed to increase with dose and duration of therapy. In animals, administration of a prostaglandin synthesis inhibitor has been shown to cause an increase in the rate of pre- and post-implantation spontaneous abortion and embryo-fetal lethality. In addition, increased incidences of various malformations, including cardiovascular ones, have been reported in animals administered a prostaglandin synthesis inhibitor during the organogenetic period. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors can expose the fetus to: - cardiopulmonary toxicity (with premature closure of the arterial duct and pulmonary hypertension); - Renal dysfunction, which can progress to renal failure with oligohydramnios; They can expose mother and newborn, at the end of pregnancy, to: - possible prolongation of bleeding time, an anti-aggregating effect that can occur even at very low doses; - inhibition of uterine contractions with consequent delay or prolongation of labor. There is a possibility of an association between the occurrence of fetal abnormalities and the intake of pseudoephedrine during the 3rd trimester of pregnancy. Breastfeeding Vicks Flu Action is contraindicated during breastfeeding (see section 4.3). Ibuprofen / pseudoephedrine have been identified in breastfed infants / children of treated patients. Data on the effects of ibuprofen / pseudoephedrine on newborns / infants do not exist or are limited in number. Fertility The effects of this drug on fertility have not been studied. The use of ibuprofen can impair fertility and is not recommended in women who are trying to conceive. Women with difficulty conceiving or undergoing fertility testing should consider discontinuing ibuprofen. There are no adequate reproductive toxicology studies on pseudoephedrine.


Side effects

The most commonly observed adverse events related to ibuprofen are gastrointestinal in nature. In general, the risk of presenting adverse events (particularly the risk of presenting serious gastrointestinal complications) increases with increasing dose and duration of treatment. Cases of hypersensitivity reactions have been reported following treatment with ibuprofen. These may consist of: (a) Nonspecific allergic reactions and anaphylaxis (b) Reactivity of the respiratory tract, including asthma, worsening of asthma, bronchospasm or dyspnoea (c) Assorted skin disorders, including rash of various types, itching, urticaria, purpura, angioedema and, more rarely, exfoliative dermatitis and bullous dermatitis (including epidermal necrolysis and erythema multiforme) Single patients with pre-existing autoimmune disease (such as systemic lupus erythematosus, mixed connective tissue disease) have been reported during treatment with ibuprofen cases of aseptic meningitis symptoms, such as neck stiffness, headache, nausea, vomiting, fever or disorientation. Edema, hypertension and heart failure have been reported in association with NSAID treatment. Clinical trials and epidemiological data suggest that the use of ibuprofen, particularly at high doses (2400 mg / day) and in long-term therapy, may be associated with a small increase in the risk of arterial thrombotic events such as myocardial infarction or stroke. (see section 4.4). The following list of adverse events relates to those that occurred with ibuprofen and pseudoephedrine hydrochloride at normal over-the-counter doses for short-term use. Additional adverse events may occur in the treatment of chronic diseases and in long-term treatment. Patients should be advised to stop taking Vicks Flu Action immediately and consult their physician if a serious adverse drug reaction occurs. The frequency of adverse reactions is defined using the following convention: very common (≥1 / 10); common (≥1 / 100 to <1/10); uncommon (≥1 / 1000 to <1/100); rare (≥1 / 10,000 to <1/1000); very rare (<1 / 10,000), frequency not known (cannot be estimated from the available data).

Infections and infestations Ibuprofen Very rare Flare-up of infectious inflammation (e.g. necrotizing fasciitis), Aseptic meningitis (neck stiffness, headache, nausea, vomiting, fever or disorientation in patients with pre-existing autoimmune disease (SLE, mixed connective tissue disease)
Disorders of the blood and lymphatic system Ibuprofen Very rare Haematopoietic disorders (anemia, leukopenia, thrombocytopenia, pancytopenia, agranulocytosis, neutropenia).
Disorders of the immune system Ibuprofen Uncommon Hypersensitivity reactions with hives, itching, rash and asthma attacks (with sharp drop in blood pressure)
  Ibuprofen and pseudoephedrine hydrochloride Very rare Severe generalized hypersensitivity reactions: signs may be face edema, angioedema, dyspnoea, bronchospasm, tachycardia, sharp drop in blood pressure, anaphylactic shock
Psychiatric disorders Ibuprofen Very rare Psychotic reactions, depression
  Pseudoephedrine hydrochloride Frequency not known Agitation, hallucinations, anxiety, behavioral abnormalities, insomnia
Nervous system disorders Ibuprofen Uncommon Central nervous system disorders such as headache, dizziness, insomnia, agitation, irritability or tiredness
  Pseudoephedrine hydrochloride Rare Frequency not known Insomnia, nervousness, anxiety, restlessness, tremors, hallucinations Haemorrhagic stroke, ischemic stroke, convulsions, headache
Eye disorders Ibuprofen Uncommon Visual disturbances
Ear and labyrinth disorders Ibuprofen Rare Tinnitus
Cardiac pathologies Ibuprofen Very rare Edema, hypertension, palpitations, heart failure, myocardial infarction
  Pseudoephedrine hydrochloride Frequency not known Palpitations, tachycardia, chest pain, arrhythmia
Vascular pathologies Ibuprofen Very rare Hypertension
  Pseudoephedrine hydrochloride Frequency not known Hypertension
Respiratory, thoracic and mediastinal disorders Pseudoephedrine hydrochloride Rare Flare-up of asthma or hypersensitivity reactions with bronchospasm
Gastrointestinal disorders Ibuprofen Common Gastrointestinal discomfort, dyspepsia, abdominal pain, nausea, vomiting, flatulence, diarrhea, anorexia, constipation, mild gastrointestinal bleeding which in rare cases leads to anemia
  Ibuprofen Uncommon Peptic ulcer, gastrointestinal perforation or haemorrhage (with melaena or haematemesis, gastritis, ulcerative stomatitis). Exacerbation of colitis and Crohn's disease (see section 4.4)
  Ibuprofen Very rare Esophagitis, pancreatitis, intestinal diaphragm stenosis
  Pseudoephedrine hydrochloride Frequency not known Dry mouth, thirst, nausea, vomiting
Hepatobiliary disorders Ibuprofen Very rare Hepatic dysfunction, liver damage, particularly in long-term therapy, liver failure, acute hepatitis
Skin and subcutaneous tissue disorders Ibuprofen Uncommon Various skin rashes:
  Ibuprofen Very rare Severe forms of skin reactions such as exfoliative dermatitis or bullous rash such as Stevens-Johnson syndrome, erythema multiforme and toxic epidermal necrolysis (Lyell's syndrome), alopecia, severe skin infections, soft tissue complications in a chickenpox infection
  Pseudoephedrine hydrochloride Frequency not known Rash, hives, itching, erythema, hyperhidrosis
Renal and urinary disorders Ibuprofen Rare Damage to kidney tissue (papillary necrosis) and high blood concentrations of uric acids
  Ibuprofen Very rare Renal and hepatic disorders, increased serum creatinine, liver disorders, edema (particularly in patients with arterial hypertension or renal insufficiency), nephrotic syndrome, interstitial nephritis, acute renal failure
  Pseudoephedrine hydrochloride Frequency not known Urinary retention in men with prostatic hypertrophy

Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit / risk ratio of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed on the website: of the Italian Medicines Agency.



Symptoms The most frequent manifestations of ibuprofen overdose are abdominal pain, nausea, vomiting, lethargy, thirst, muscle weakness, drowsiness, blurred vision and dizziness. Other undesirable effects may occur, including headache, tinnitus, CNS depression, convulsions, hypotension, bradycardia, tachycardia, supraventricular and ventricular arrhythmias and atrial fibrillation. Metabolic acidosis, coma, acute renal failure, hyperkalaemia, apnea (especially in young children), respiratory depression and respiratory failure have been reported rarely. Worsening of asthma is possible in asthmatics. Signs and symptoms of pseudoephedrine overdose include irritability, insomnia, fever, sweating, anxiety, restlessness, tremors, seizures, palpitations (sinus arrhythmia), hypotension, dry mouth and difficulty urinating. Hallucinations have been reported (more likely in children). Treatment Treatment of overdose is supportive. Gastric lavage and activated charcoal may be benefited within 1 hour of ingesting a potentially toxic amount, and correcting serum electrolytes if necessary. Symptomatic and supportive treatment should be undertaken, particularly with regard to the cardiovascular and respiratory systems. For example, severe hypertension may need to be treated with an alpha-blocker drug, while the use of a beta-blocker may be required to control cardiac arrhythmias. Seizures can be controlled with intravenous diazepam, while chlorpromazine can be used for extreme excitability and hallucinations.



Combination of pseudoephedrine with : Possible reactions
Non-selective monoamine oxidase inhibitors (MAOIs): Vicks Flu Action should not be taken by patients on current or past (last two weeks) therapy with monoamine oxidase inhibitors (MAOIs), as there is a risk of hypertensive episodes such as paroxysmal hypertension and hyperthermia, which can be fatal (see section 4.3 ).
Other indirectly acting sympathomimetics or vasoconstrictors, administered orally or nasally, to sympathomimetic drugs, phenylpropanolamine, phenylephrine, ephedrine, methylphenidate: Pseudoephedrine may potentiate the effect of other sympathomimetics (vasoconstrictors) and cause a risk of vasoconstriction and / or hypertensive crisis.
Reversible inhibitors of monoamine oxidase A (RIMA), Linezolid, ergot alkaloids with dopaminergic action, ergot alkaloid vasoconstrictors: Risk of vasoconstriction and / or hypertensive crisis.
Volatile halogenated anesthetics: Acute perioperative hypertension. In elective surgery, discontinue treatment with Vicks Flu Action several days before surgery.
Guanethidine, reserpine and methyldopa: The effect of pseudoephedrine may be reduced.
Tricyclic antidepressants: The effect of pseudoephedrine may be reduced or increased.
Digitalis, quinidine or tricyclic antidepressants: Increased frequency of arrhythmia.


Concomitant use of ibuprofen with : Possible reactions
Other NSAIDs, salicylates, analgesics, antipyretics and COX 2: Concomitant administration of various NSAIDs, analgesics, antipyretics and selective COX 2 inhibitors may increase the risk of adverse reactions such as gastrointestinal ulcers and bleeding due to a synergistic effect. Concomitant use of Vicks Flu Action with these drugs should therefore be avoided (see section 4.4).
Cardiac glycosides (such as digoxin): Concomitant use with digoxin preparations may increase serum levels of cardiac glycosides (digoxin). With proper use (up to 5 days), a check of serum digoxin levels is usually not necessary.
Corticosteroids: Corticosteroids may increase the risk of adverse reactions, particularly of the gastrointestinal tract (gastrointestinal ulcer or bleeding) (see section 4.3).
Antiplatelet drugs: Increased risk of gastrointestinal bleeding (see section 4.4).
Acetylsalicylic acid (low dosage): Concomitant administration of acetylsalicylic acid with a daily dose greater than 75 mg should be avoided due to an increased risk of adverse reactions (see section 4.3).
Anticoagulants: (e.g., warfarin, ticlopidine, clopidogrel, tirofiban, eptifibatide, abciximab, iloprost) Increased risk of gastrointestinal bleeding, because NSAIDs such as ibuprofen may enhance the effect of anticoagulants (see section 4.4)
Phenytoin: Concomitant use of Vicks Flu Action and phenytoin preparations could increase the serum levels of these medicinal products. With proper use (up to 5 days), a check of serum phenytoin levels is usually not necessary.
Selective Serotonin Reuptake Inhibitors (SSRIs): Increased risk of gastrointestinal bleeding (see section 4.4).
Lithium: Concomitant use of Vicks Flu Action and lithium-based preparations could increase the serum levels of these medicinal products. With proper use (up to 5 days), a check of serum lithium levels is usually not necessary.
Probenecid and sulfinpyrazone: Medicinal products containing probenecid or sulfinpyrazone may delay the excretion of ibuprofen.
Diuretics, ACE inhibitors, beta blockers and angiotensin-II antagonists: NSAIDs can reduce the effect of diuretics and other antihypertensive drugs. In some patients with impaired renal function (e.g. dehydrated patients or elderly patients with impaired renal function) the concomitant administration of an ACE inhibitor, a beta blocker or an angiotensin-II antagonist and drugs that inhibit cyclo-oxygenase may cause further deterioration renal function, including possible acute renal failure, usually reversible. Therefore, the administration of these drugs in combination should be done with caution, especially in elderly patients. Patients should be adequately hydrated and monitoring of renal function should be considered after initiation of treatment and on a periodic basis thereafter.
Potassium-sparing diuretics: Concomitant administration of Vicks Flu Action and potassium-sparing diuretics may cause hyperkalaemia (monitoring of serum potassium levels is recommended).
Methotrexate: Administration of Vicks Flu Action within 24 hours before or after methotrexate administration may cause high concentrations of methotrexate and an increase in its toxic effects.
Ciclosporin: The risk of a damaging effect to the kidneys from cyclosporine increases with concomitant administration of some non-steroidal anti-inflammatory drugs. This effect cannot be excluded even for the association between cyclosporine and ibuprofen.
Tacrolimus: The risk of nephrotoxicity increases if the two medicinal products are administered in combination.
Zidovudine: There have been reports of an increased risk of haemarthrosis and hematoma in HIV (+) haemophiliac patients receiving concomitant therapy with zidovudine and ibuprofen.
Sulfonylureas: Clinical studies have shown interactions between non-steroidal anti-inflammatory drugs and antidiabetic drugs (sulfonylureas). Although no interactions between sulfonylureas and ibuprofen have been described, it is recommended that blood glucose values be monitored as a precaution during concomitant administration.
Quinolone antibiotics: Animal data indicate that NSAIDs may increase the risk of seizures associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of developing seizures.
Heparin; Gingko biloba: Increased risk of bleeding.


Storage and packaging

Vicks flu action tablets are sold in blister packs of 12 tablets, it is important to keep the product away from sources of heat and humidity, keep out of reach of children.



Discover Vicks products